logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics team discuss major multi-target deal with AstraZeneca

Silence Therapeutics (LON:SLN) chief financial officer Rob Quinn and head of business development John Strafford discuss this week's 'transformational' deal they've struck with major AstraZeneca.

It's worth US$80mln in cash and investment upfront, plus a further US$400mln in milestone payments and royalties for each disease area targeted.

Using Silence’s small interfering RNA, or siRNA technology, AstraZeneca is looking to initially develop treatments for liver, heart and lung diseases.

Quick facts: Silence Therapeutics PLC

Price: 453 GBX

AIM:SLN
Market: AIM
Market Cap: £375.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics feels move to NASDAQ will give its tech the...

Silence Therapeutics PLC's (LON:SLN) chairman Iain Ross and CFO Rob Quinn speak to Proactive London's Andrew Scott after announcing its intention to list on the American growth market, Nasdaq. Ross says in the US, RNAi is very hot at the moment and if you look at their competitor companies...

1 week, 2 days ago

2 min read